PHIRE!� Xtreme Metabolic Fat-Loss Technology
PHIRE!� is a revolutionary pharmaceutical-grade fat loss formula
specifically designed to boost your metabolism and heighten your energy levels.
PHIRE!��s scientifically designed mixture of ingredients are brought
together as a powerhouse team to eradicate undesired fat where it matters most!
Ground breaking ingredients such as Evodiamine and Forskolin have been shown to
utilize stored body fat for energy, naturally increasing the body�s metabolism.
In addition, PHIRE!� is formulated with Caffeine, Yohimbe and Tyrosine to
increase energy, mental alertness and focus. Stop spinning your wheels with
inefficient fat loss products and upgrade to Axis Labs� PHIRE!�, the
Xtreme Metabolic that will make you forget all about ephedra. Get PHIRE!�
now to help you expose your hardest core ever!
Product Highlights:
� Powerful Source of Energy and Increases Mental Alertness and Focus
� Decreases Fatigue
� Maintains Muscle Tone
� Utilizes Stored Body Fat for Fuel
� Optimizes Cardiovascular Function [increases capillary dilation]
� Suppresses Appetite
� Supports Energy Metabolism and Helps the Body with the Breakdown of Fat and
Carbohydrates
� Supports Thyroid Production to Ramp Up Metabolism
� Enhanced Feeling of Well Being
� Enhanced Insulin Secretion and Sensitivity
What is PHIRE!� made up of that makes it such a powerful fat burning
supplement?
Evodiamine
Evodiamine is a bioactive alkaloid extract from a plant called Evodiae Fructus.
This is a Chinese herb named Wu-Chu-Yu that Chinese herbalists have used for
centuries as a weight loss supplement. Evodiamine is related to capsaicin or the
spicy flavor of peppers. It acts as a vanilloid receptor agonist, and can
enhance lipolytic (breakdown of fat) activity, enhance insulin secretion and
sensitivity.
Interestingly enough, Evodiamine can raise the body�s skin temperature while
simultaneously decreasing core temperature, similar to a hypothermic state.
Studies have shown that this is an effective process to burn calories and fat
for energy while the body increases its temperature.
Forskolin
Froskolin is a diterpene found in the root of an Indian plant called Coleus
Forskohlii (part of the mint family of plants). In the body, Forskolin activates
an enzyme that raises levels of a key cell-regulating substance called cAMP
(cyclic adenosine monophosphate). Increased cellular cAMP levels cause numerous
physiological and biochemical effects such as increased insulin secretion,
increased thyroid function (and therefore metabolic rate), reduced adipose
assimilation and increased lipolysis (the breakdown of fats). Forskolin can also
increase blood flow and capillary dilation.
Thiamine
Thiaming helps support energy metabolism and assists the body with the breakdown
of fat, and carbohydrates. Every cell of the body requires vitamin B1 to form
ATP from the break down of fat and carbohydrates. Thiamine keeps your mucous
membranes healthy and is essential for nervous system, cardiovascular and
muscular function, and it also helps maintain muscle tone.
Niacin
Niacin helps support energy metabolism and assists the body with the breakdown
of fat, carbohydrates. Niacin helps fuel your body by converting blood sugar
into energy, and assists in the release of energy from the metabolism of
carbohydrates, fats, and proteins. Niacin is also necessary for the synthesis of
secondary sex hormones.
Yohimbine
Yohimbine, an alkaloid, is the primary active ingredient of yohimbe. Yohimbine
increases the amount of adrenergic activity in the body, increasing levels of
norepinephrine and stimulation of the central nervous system. In addition,
Yohimbine has shown to increase lipolysis (the breaking down of fat). Yohimbine
has also shown to be an appetite suppressant, potentially reducing caloric
intake. It has also been shown to enhance insulin secretion and sensitivity.
Caffeine
Caffine has Thermogenic properties and increases lipolysis (fat break down).
Caffine can suppress appetite, decrease fatigue, and increase alertness and work
capacity, which can be very beneficial for endurance exercise. Caffine acts as a
stimulant and has a synergistic effect with norepinephrine and other
catecholamines like ephedrine and possibly yohimbine. Thermogenic and stimulant
effects can be greatly increased through the synergistic effect of caffine.
L-Tyrosine
L-Tyrosine is essential amino acid that is a building block of protein and is
necessary for maintaining proper brain function. L-Tyrosine is a precursor to
the adrenal hormones norepinephrine, epinephrine, dopamine and to thyroid
hormones. Because L-Tyrosine is a precursor of dopamine, supplementing with
L-Tyrosine may increase feelings of well being, heighten mental alertness and
offset physical and mental fatigue. L-Tyrosine has also show to suppress
appetite, potentially reducing caloric intake.
|
Supplement Facts
Serving Size: 2 Mini-Caps
Servings per Container: 60
|
| |
Amount Per Serving |
*%DV |
| Vitamin B1 (Thiamine) |
25mg |
1666% |
| Vitamin B3 (Niacin) |
25mg |
125% |
| Caffeine Anhydrous |
200mg |
� |
| Yohimbe (3% Yohimbine) |
100mg |
� |
| Evodiamine 98% |
50mg |
� |
| Coleus Forskohli (40% Forskolin) |
50mg |
� |
| L-Tyrosine |
50mg |
� |
*Daily value (DV) are based on a 2000 calorie
diet
�Daily value (DV) not established |
Other Ingredients: Dicalcium Phosphate, Gelatin, purified water, Magnesium
Stearate, Silica.
Directions: As a dietary supplement, take 1-2 capsules, 30 minutes prior to
breakfast and 1-2 capsules in the early afternoon. Do not take 6 hours prior to
bed because PHIRE!� may interfere with sleep. For best results, use in
conjunction with a reduced caloric diet and cardiovascular exercise program.
Store in a cool place. Protect from heat, light and moisture.
WARNING: KEEP OUT OF REACH OF CHILDREN. Not for use by individuals under the age
of 18 or elderly. Consult a physician before using this or any dietary
supplements. Do not use if pregnant, nursing or chronically ill. This product is
not intended for individuals who are at risk of or have been treated for high
blood pressure, heart disease, thyroid disease, depression or other psychiatric
condition, renal disease, reoccurring headaches, spasms, has asthma or taking
asthma medication or if your are using a MAO inhibitor.
Manufactured with pride in the USA.
PHIRE� is a registered trademark of Axis Labs� REFRENCES:
Evodiamine
1) Kobayashi, Y., Y. Nakano, M. Kizaki, K. Hoshikuma, Y. Yokoo and T. Kamiya
(2001). Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia
rutaecarpa, a vanilloid receptor agonist. Planta Med 67(7): 628-33.
2) Komatsu, K., K. Wakame and Y. Kano (1993). Pharmacological properties of
galenical preparation. XVI. Pharmacokinetics of evodiamine and the metabolite in
rats. Biol Pharm Bull 16(9): 935-8.
3) Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg
PM. (2004). Evodiamine functions as an agonist for the vanilloid receptor TRPV1.
Org Biomol Chem. Aug 21;2(16):2281-6. Epub 2004 Jul 27.
4) Tsai, T. H., T. F. Lee, C. F. Chen and L. C. Wang (1995). Thermoregulatory
effects of alkaloids isolated from Wu-chu-yu in afebrile and febrile rats.
Pharmacol Biochem Behav 50(2): 293-8.
Tyrosine
5) Banderet, LE, and Lieberman HR. (1989). Treatment with tyrosine, a
neurotransmitter precursor, reduces environmental stress in humans. Brain Res
Bull 22: 759-762.
6) Gelenberg AJ, Gibson CJ, Wojcik JD. (1982). Neurotransmitter precursors for
the treatment of depression. Psychopharmacol Bull 18:7-18.
7) Harmer CJ, McTavish SF, Clark L, Goodwin GM, Cowen PJ. (2001). Tyrosine
depletion attenuates dopamine function in healthy volunteers. Psychopharmacology
(Berl). Feb;154(1):105-11.
8) Hull KM, Maher TJ. (1990). L-tyrosine potentiates the anorexia induced by
mixed-acting sympathomimetic drugs in hyperphagic rats. J Pharmacol Exp Ther.
Nov;255(2):403-9.
9) Lieberman, HR, Corkin S, Spring BJ, Wurtman RJ, and Growden JH. (1985). The
effects of dietary neurotransmitter precursors on human behavior. Am J Clin Nutr
42: 366-370.
10) Roberts SA, Thorpe JM, Ball RO, Pencharz PB. (2001). Tyrosine requirement of
healthy men receiving a fixed phenylalanine intake determined by using indicator
amino acid oxidation. Am J Clin Nutr. Feb;73(2):276-82.
11) Romanowski, W, and Grabiec S. (1974). The role of serotonin in the mechanism
of central fatigue. Acta Physiol Pol 25: 127-134.
Caffeine
12) Hespel P, Op't Eijnde B, Van Leemputte M. (2002). Opposite actions of
caffeine and creatine on muscle relaxation time in humans. J Appl Physiol.
Feb;92(2):513-8.
13) Kourtidou-Papadeli C, Papadelis C, Louizos AL, Guiba-Tziampiri O. (2002).
Maximum cognitive performance and physiological time trend measurements after
caffeine intake. Cogn Brain Res. May;13(3):407-15.
14) Papadelis C, Kourtidou-Papadeli C, Vlachogiannis E, Skepastianos P, Bamidis
P, Maglaveras N, Pappas K. (2003). Effects of mental workload and caffeine on
catecholamines and blood pressure compared to performance variations. Brain Cogn.
Feb;51(1):143-54.
15) Plaskett CJ, Cafarelli E. (2001). Caffeine increases endurance and
attenuates force sensation during submaximal isometric contractions. J Appl
Physiol. Oct;91(4):1535-44.
Forskolin
16) Borea, P. A., K. Varani, A. Dalpiaz, A. Capuzzo, E. Fabbri and I. J. AP
(1994). Full and partial agonistic behaviour and thermodynamic binding
parameters of adenosine A1 receptor ligands. Eur J Pharmacol 267(1): 55-61.
17) Chaudhry, A. and J. G. Granneman (1991). Developmental changes in adenylyl
cyclase and GTP binding proteins in brown fat. Am J Physiol 261(2 Pt 2):
R403-11.
18) Chaudhry, A. and J. G. Granneman (1997). Effect of hypothyroidism on
adenylyl cyclase activity and subtype gene expression in brown adipose tissue.
Am J Physiol 273(2 Pt 2): R762-7.
19) Deng, C., M. Moinat, L. Curtis, A. Nadakal, F. Preitner, O. Boss, F.
Assimacopoulos-Jeannet, J. Seydoux and J. P. Giacobino (1997). Effects of beta-adrenoceptor
subtype stimulation on obese gene messenger ribonucleic acid and on leptin
secretion in mouse brown adipocytes differentiated in culture. Endocrinology
138(2): 548-52.
20) Dolgacheva, L. P., B. B. Abzhalelov, S. J. Zhang, V. P. Zinchenko and G. E.
Bronnikov (2003). Norepinephrine induces slow calcium signalling in murine brown
preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway. Cell
Signal 15(2): 209-16.
21) Dubey MP, Srimal RC, Nityanand S, Dhawan BN. (1981). Pharmacological studies
on coleonol, a hypotensive diterpene from Coleus forskohlii. J Ethnopharmacol
Jan;3(1):1-13.
22) Gesta, S., K. Lolmede, D. Daviaud, M. Berlan, A. Bouloumie, M. Lafontan, P.
Valet and J. S. Saulnier-Blache (2003). Culture of human adipose tissue explants
leads to profound alteration of adipocyte gene expression. Horm Metab Res 35(3):
158-63.
23) Hellmer, J., C. Marcus, T. Sonnenfeld and P. Arner (1992). Mechanisms for
differences in lipolysis between human subcutaneous and omental fat cells. J
Clin Endocrinol Metab 75(1): 15-20.
24) Hellstrom, L., S. Rossner, E. Hagstrom-Toft and S. Reynisdottir (1997).
Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a
metabolic predictor of weight loss in obese subjects. Int J Obes Relat Metab
Disord 21(4): 314-20.
25) Ho, R. and Q. H. Shi (1982). Forskolin as a novel lipolytic agent. Biochem
Biophys Res Commun 107(1): 157-64.
26) Honnor, R. C., G. S. Dhillon and C. Londos (1985). cAMP-dependent protein
kinase and lipolysis in rat adipocytes. II. Definition of steady-state
relationship with lipolytic and antilipolytic modulators. J Biol Chem 260(28):
15130-8.
27) Imbeault P, Tremblay A, Despres J, Mauriege P. (2000). Beta-adrenoceptor-stimulated
lipolysis of subcutaneous abdominal adipocytes as a determinant of fat oxidation
in obese men. Eur J Clin Invest Apr;30(4):290-6.
28) Imbeault, P., D. Prud'Homme, A. Tremblay, J. P. Despres and P. Mauriege
(2000). Adipose tissue metabolism in young and middle-aged men after control for
total body fatness. J Clin Endocrinol Metab 85(7): 2455-62.
29) Lofgren P, Hoffstedt J, Ryden M, Thorne A, Holm C, Wahrenberg H, Arner P.
(2002). Major gender differences in the lipolytic capacity of abdominal
subcutaneous fat cells in obesity observed before and after long-term weight
reduction. J Clin Endocrinol Metab Feb;87(2):764-71.
30) Litosch, I., T. H. Hudson, I. Mills, S. Y. Li and J. N. Fain (1982).
Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat
adipocytes. Mol Pharmacol 22(1): 109-15.
31) Malbon, C. C. and M. P. Graziano (1983). Adenosine deaminase normalizes
cyclic AMP responses of hypothyroid rat fat cells to forskolin, but not
beta-adrenergic agonists. FEBS Lett 155(1): 35-8.
32) Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. (2002). Defining
thyrotropin-dependent and -independent steps of thyroid hormone synthesis by
using thyrotropin receptor-null mice. Proc Natl Acad Sci U S A Nov
26;99(24):15776-81.
33) Nakagaki, I., S. Sasaki, T. Yahata, H. Takasaki and S. Hori (2005).
Cytoplasmic and mitochondrial Ca levels in brown adipocytes. Acta Physiol Scand
183(1): 89-97.
34) Ottosson, M., P. Lonnroth, P. Bjorntorp and S. Eden (2000). Effects of
cortisol and growth hormone on lipolysis in human adipose tissue. J Clin
Endocrinol Metab 85(2): 799-803.
35) Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, Hammond HK. (2002).
Adenylyl cyclase increases survival in cardiomyopathy. Apr 23;105(16):1989-94
36) Scarpace, P. J., L. A. Baresi and J. E. Morley (1987). Modulation of
receptors and adenylate cyclase activity during sucrose feeding, food
deprivation, and cold exposure. Am J Physiol 253(6 Pt 1): E629-35.
37) Simon, E., M. T. Macarulla, A. Fernandez-Quintela, V. M. Rodriguez and M. P.
Portillo (2005). Body fat-lowering effect of conjugated linoleic acid is not due
to increased lipolysis. J Physiol Biochem 61(2): 363-9.
38) Zhang, S. R., Q. H. Shi and R. J. Ho (1983). Cyclic AMP-lowering mediator of
insulin. J Biol Chem 258(10): 6471-6.
39) Zhang XP, Tada H, Wang Z, Hintze TH. (2002). cAMP signal transduction, a
potential compensatory pathway for coronary endothelial NO production after
heart failure. Arterioscler Thromb Vasc Biol Aug 1;22(8):1273-8.
Yohimbe
40) Currie PJ, Wilson LM. (1992). Yohimbine attenuates clonidine-induced feeding
and macronutrient selection in genetically obese (ob/ob) mice. Pharmacol Biochem
Behav. Dec;43(4):1039-46
41) Galitzky J, Lafontan M, Nordenstrom J, Arner P. (1993). Role of vascular
alpha-2 adrenoceptors in regulating lipid mobilization from human adipose
tissue. J Clin Invest. May;91(5):1997-2003.
42) Galitzky J, Riviere D, Tran MA, Montastruc JL, Berlan M. (1990).
Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers.
Eur J Clin Pharmacol. 39(5):447-51.
43) Galitzky J, Taouis M, Berlan M, Riviere D, Garrigues M, Lafontan M. (1988).
Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid
mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin
Invest. Dec;18(6):587-94
44) Gomez-Ambrosi J, Fruhbeck G, Aguado M, Milagro FI, Margareto J, Martinez AJ.
(2001). Divergent effects of an alpha2-adrenergic antagonist on lipolysis and
thermogenesis: interactions with a beta3-adrenergic agonist in rats. Int J Mol
Med. Jul;8(1):103-9
45) Kucio C, Jonderko K, Piskorska D. (1991). Does yohimbine act as a slimming
drug? Isr J Med Sci. Oct;27(10):550-6.
46) Le Corre P, Dollo G, Chevanne F, Le Verge R. (1999). Biopharmaceutics and
metabolism of yohimbine in humans. Eur J Pharm Sci. Oct;9(1):79-84
47) Tam SW, Worcel M, Wyllie M. (2001). Yohimbine: a clinical review. Pharmacol
Ther. Sep;91(3):215-43
Thiamine
48) Guy-Grand, B., G. Dorf, J. Duchier and P. Aimez (1972). Dietetics and
nutrition in 1972. Rev Prat 22(6): 743-62.
49) Hobara, R., H. Kato and K. Sakamoto (1983). Effect of thiamine and thiamine
levels on experimental alloxan induced diabetes mellitus. Jpn J Pharmacol 33(1):
27-31.
50) Johnson, R. E., J. A. Mastropaolo and M. A. Wharton (1972). Exercise,
dietary intake, and body composition. J Am Diet Assoc 61(4): 399-403.
51) Kirchgessner, M., D. A. Roth-Maier, U. Heindl and F. J. Schwarz (1995).
B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of
growing cattle of the German Simmental breed under different feeding
intensities. Z Lebensm Unters Forsch 201(1): 20-4.
52) Lemonnier, D., P. de Gasquet, S. Griglio, R. Naon, F. Reynouard and J.
Tremolieres (1974). Effect of dietary vitamin B level on fat storage, adipose
tissue cellularity and energy expenditure in rats and mice fed a high-fat diet.
Nutr Metab 16(1): 15-29.
53) Mehlman, M. A., R. B. Tobin, M. M. Madappally and H. K. Hahn (1971). Mode of
action of aspirin. Effect of dietary aspirin on mitochondrial pyruvate
metabolism in normal and thiamine-deficient rats. J Biol Chem 246(6): 1618-22.
54) Muroyama, K., S. Murosaki, Y. Yamamoto, A. Ishijima and Y. Toh (2003).
Effects of intake of a mixture of thiamin, arginine, caffeine, and citric acid
on adiposity in healthy subjects with high percent body fat. Biosci Biotechnol
Biochem 67(11): 2325-33.
55) Muroyama, K., S. Murosaki, Y. Yamamoto, H. Odaka, H. C. Chung and M. Miyoshi
(2003). Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and
citric acid in non-insulin dependent diabetic KK mice. J Nutr Sci Vitaminol
(Tokyo) 49(1): 56-63.
56) Rieder, H. P., W. Berger and R. Fridrich (1980). Vitamin status in diabetic
neuropathy (thiamine, riboflavin, pyridoxin, cobalamin and tocopherol). Z
Ernahrungswiss 19(1): 1-13.
Niacin
57) Carlson, L. A. (1963). Studies on the effect of nicotinic acid on
catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand
173: 719-22.
58) Carlson, L. A. and J. Ostman (1965). Inhibition Of The Mobilization Of Free
Fatty Acids From Adipose Tissue In Diabetes. Ii. Effect Of Nicotinic Acid And
Acetylsalicylate On Blood Glucose In Human Diabetics. Acta Med Scand 178: 71-9.
59) Gaion, R. M., L. Murari, L. Cima, P. Valenti and P. Da Re (1985).
Antilipolytic activity of tiadenol-nicotinate in isolated fat cells: a
comparison with its parent drugs. Drugs Exp Clin Res 11(6): 407-11.
60) Grunfeld, C. and J. K. Shigenaga (1984). Nicotinamide and other inhibitors
of ADP-ribosylation block deoxyglucose uptake in cultured cells. Biochem Biophys
Res Commun 123(2): 785-91.
61) Hotz, W. (1983). Nicotinic acid and its derivatives: a short survey. Adv
Lipid Res 20: 195-217.
62) Howald, H. and J. Decombaz (1983). Nutrient intake and energy regulation in
physical exercise. Experientia Suppl 44: 77-88.
63) Lee, H. M., R. M. Ellis and M. V. Sigal, Jr. (1961). Some insulin-like
effects of nicotinic acid observed with isolated rat epididymal adipose tissue.
Biochim Biophys Acta 49: 408-10.
64) Ostman, J. (1964). Effect Of Nicotinic Acid On The Fatty Acid Metabolism Of
Adipose Tissue In Alloxan Diabetic Rats. Metabolism 13: 675-80.
65) Ostman, J. (1965). Inhibitory Effect Of Nicotinic Acid On Ffa Mobilization
In Alloxan-Diabetic Rats. Ii. A Comparison Of The Effect Of Nicotinic Acid And
Salicylate On The Fatty Acid Metabolism And Glucose Uptake By Adipose Tissue In
Vitro. Acta Med Scand 177: 623-9.
66) Schnare, D. W., G. Denk, M. Shields and S. Brunton (1982). Evaluation of a
detoxification regimen for fat stored xenobiotics. Med Hypotheses 9(3): 265-82.
67) Walldius, G. and G. Wahlberg (1985). Effects of nicotinic acid and its
derivatives on lipid metabolism and other metabolic factors related to
atherosclerosis. Adv Exp Med Biol 183: 281-93.
|
